Strength signal in the chart:
1. Mark-up stage
2. Pullback with shakeout
3. Green pentagon buy signal
Hit the "LIKE" button to support us :)
This information only serves as reference information and does not constitute a buy or sell call. Conduct your own research and assessment before deciding to buy or sell any stock
Interesting company ,
I don't really like taking swing positions in biotech companies because I find they are somewhat unstable , lots can happen to gap a price down or up in a short amount of time.
Also, I do not have a medical background , so its kind of like reading a different language when you take some time to research the companies website ect.
It is breaking the buy point out today. The volume is about to exceed the average. watch for channel resistances.
12 months Consensus Price Target: $18.57
if you find my charts useful, please leave me "like" or "comment".
Please don't trade according to the ideas, rely on your own knowledge.
Analysis done on 25/05/2020
→ 20 & 40 SMA sloping up
→ 20MA > 40MA
Awaiting buy trigger
→ CCI <-100
→ Low of daily bar touches 20MA or goes below 20MA
→ Close above 40MA
→ Buy 1 bid above previous day high
→ Sell 5 bars later exclusive of initial bar
→ 50% below price bought
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is...
Bad movement today,
unfortunately due to a "bad" annual finance report, personally I do think the management has taken a good decision with cost reduction for the next 2 years.
Consolidation of R&D activities in one location (Israel). Positions and operations eliminated will also reduce overlapping R&D and G&A activities in Israel and the United States;
HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology...
above cloud see in our book on amazon important reason of cloud macd about to cross
relative strength strong
money flow excellent please diversify between candidates use good money
management in our book
profit target at 6.60 USD. I suppose we have an HPS setup with the trend line divergences, the undersold stochastics indicator, the very much undersold relative strength index and the MACD line intersecting the signal line
It seems to me that it will bounce back off the support line one more time and possibly have a breakout over the resistance level. good luck...